Citi analyst Samantha Semenkow raised the firm’s price target on Biohaven (BHVN) to $17 from $14 and keeps a Buy rating on the shares. The firm sees an attractive risk/reward at current share levels into the company’s 2026 catalysts. Citi believes recent competitor data in focal epilepsy are very positive for Biohaven’s Phase 3 opakalim trial, which has a readout in the second half of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven completes enrollment in Phase 2 study on taldefgrobep alfa
- Biohaven price target raised to $30 from $15 at TD Cowen
- Biohaven price target raised to $27 from $24 at Goldman Sachs
- Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
- Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target